Article: A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleA new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B
AuthorsSeto, WK3
Lee, CF1 2
Lai, CL3
Ip, PPC3
Fong, YT3
Fung, J3
Wong, KH3
Yuen, MF3
Issue Date2011
PublisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
CitationPlos One, 2011, v. 6 n. 8 [How to Cite?]
DOI: http://dx.doi.org/10.1371/journal.pone.0023077
AbstractObjective: We developed a predictive model for significant fibrosis in chronic hepatitis B (CHB) based on routinely available clinical parameters. Methods: 237 treatment-naïve CHB patients [58.4% hepatitis B e antigen (HBeAg)-positive] who had undergone liver biopsy were randomly divided into two cohorts: training group (n = 108) and validation group (n = 129). Liver histology was assessed for fibrosis. All common demographics, viral serology, viral load and liver biochemistry were analyzed. Results: Based on 12 available clinical parameters (age, sex, HBeAg status, HBV DNA, platelet, albumin, bilirubin, ALT, AST, ALP, GGT and AFP), a model to predict significant liver fibrosis (Ishak fibrosis score ≥3) was derived using the five best parameters (age, ALP, AST, AFP and platelet). Using the formula log(index+1) = 0.025+0.0031(age)+0.1483 log(ALP)+0.004 log(AST)+0.0908 log(AFP+1)-0.028 log(platelet), the PAPAS (Platelet/Age/Phosphatase/AFP/AST) index predicts significant fibrosis with an area under the receiving operating characteristics (AUROC) curve of 0.776 [0.797 for patients with ALT <2×upper limit of normal (ULN)] The negative predictive value to exclude significant fibrosis was 88.4%. This predictive power is superior to other non-invasive models using common parameters, including the AST/platelet/GGT/AFP (APGA) index, AST/platelet ratio index (APRI), and the FIB-4 index (AUROC of 0.757, 0.708 and 0.723 respectively). Using the PAPAS index, 67.5% of liver biopsies for patients being considered for treatment with ALT <2×ULN could be avoided. Conclusion: The PAPAS index can predict and exclude significant fibrosis, and may reduce the need for liver biopsy in CHB patients. © 2011 Seto et al.
ISSN1932-6203
2011 Impact Factor: 4.092
2011 SCImago Journal Rankings: 0.519
DOIhttp://dx.doi.org/10.1371/journal.pone.0023077
PubMed Central IDPMC3154931
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorSeto, WK
dc.contributor.authorLee, CF
dc.contributor.authorLai, CL
dc.contributor.authorIp, PPC
dc.contributor.authorFong, YT
dc.contributor.authorFung, J
dc.contributor.authorWong, KH
dc.contributor.authorYuen, MF
dc.date.accessioned2011-10-28T02:44:55Z
dc.date.available2011-10-28T02:44:55Z
dc.date.issued2011
dc.description.abstractObjective: We developed a predictive model for significant fibrosis in chronic hepatitis B (CHB) based on routinely available clinical parameters. Methods: 237 treatment-naïve CHB patients [58.4% hepatitis B e antigen (HBeAg)-positive] who had undergone liver biopsy were randomly divided into two cohorts: training group (n = 108) and validation group (n = 129). Liver histology was assessed for fibrosis. All common demographics, viral serology, viral load and liver biochemistry were analyzed. Results: Based on 12 available clinical parameters (age, sex, HBeAg status, HBV DNA, platelet, albumin, bilirubin, ALT, AST, ALP, GGT and AFP), a model to predict significant liver fibrosis (Ishak fibrosis score ≥3) was derived using the five best parameters (age, ALP, AST, AFP and platelet). Using the formula log(index+1) = 0.025+0.0031(age)+0.1483 log(ALP)+0.004 log(AST)+0.0908 log(AFP+1)-0.028 log(platelet), the PAPAS (Platelet/Age/Phosphatase/AFP/AST) index predicts significant fibrosis with an area under the receiving operating characteristics (AUROC) curve of 0.776 [0.797 for patients with ALT <2×upper limit of normal (ULN)] The negative predictive value to exclude significant fibrosis was 88.4%. This predictive power is superior to other non-invasive models using common parameters, including the AST/platelet/GGT/AFP (APGA) index, AST/platelet ratio index (APRI), and the FIB-4 index (AUROC of 0.757, 0.708 and 0.723 respectively). Using the PAPAS index, 67.5% of liver biopsies for patients being considered for treatment with ALT <2×ULN could be avoided. Conclusion: The PAPAS index can predict and exclude significant fibrosis, and may reduce the need for liver biopsy in CHB patients. © 2011 Seto et al.
dc.description.naturepublished_or_final_version
dc.identifier.citationPlos One, 2011, v. 6 n. 8 [How to Cite?]
DOI: http://dx.doi.org/10.1371/journal.pone.0023077
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0023077
dc.identifier.epagee23077
dc.identifier.hkuros196658
dc.identifier.hkuros213690
dc.identifier.isiWOS:000293953400025
dc.identifier.issn1932-6203
2011 Impact Factor: 4.092
2011 SCImago Journal Rankings: 0.519
dc.identifier.issue8
dc.identifier.pmcidPMC3154931
dc.identifier.pmid21853071
dc.identifier.scopuseid_2-s2.0-80051604371
dc.identifier.spagee23077
dc.identifier.urihttp://hdl.handle.net/10722/142388
dc.identifier.volume6
dc.languageeng
dc.publisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
dc.publisher.placeUnited States
dc.relation.ispartofPLoS ONE
dc.relation.referencesReferences in Scopus
dc.subject.meshHepatitis B, Chronic - complications - diagnosis
dc.subject.meshLiver Cirrhosis - complications - diagnosis
dc.subject.meshModels, Biological
dc.subject.meshPredictive Value of Tests
dc.subject.meshReproducibility of Results
dc.titleA new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B
dc.typeArticle
Author Affiliations
  1. Duke-NUS Graduate Medical School Singapore
  2. Singapore Clinical Research Institute
  3. The University of Hong Kong